Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic

Journal of Diabetes

Volumn 8, Issue 2, 2016, Pages 279-285

  Kannan, Subramanian ^a   Pantalone, Kevin M ^b   Matsuda, Simone ^b   Wells, Brian J ^c   Karafa, Matthew ^b   Zimmerman, Robert S ^b  

^a Multispecialty Hospital Shaw Mazumdar Medical Centre   (India)

^b LERNER RESEARCH INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Congestive heart failure; Dipeptidyl peptidase 4 inhibitors; Mortality; Sulfonylureas; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; SULFONYLUREA; 2,4-THIAZOLIDINEDIONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; PEPTIDE FRAGMENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA BASE; DEATH; DIABETIC PATIENT; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; HEART FAILURE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AGED; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; SURVIVAL RATE; THIAZOLIDINEDIONES;

EID: 84959154541     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12301     Document Type: Article

References (27)

1. Nathan DM, Buse JB, Davidson MB etal. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
2. Garber AJ, Abrahamson MJ, Barzilay JI etal. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013; 19: 327-336.
3. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
4. Nathan DM, Buse JB, Kahn SE etal. Rationale and design of the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE). Diabetes Care. 2013; 36: 2254-2261.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-865.
6. Horsdal HT, Johnsen SP, Sondergaard F etal. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: A population-based follow-up study. Diabetes Metab Res Rev. 2009; 25: 515-522.
7. Pantalone KM, Kattan MW, Yu C etal. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: A retrospective analysis. Diabetes Care. 2010; 33: 1224-1229.
8. Zeller M, Danchin N, Simon D etal. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010; 95: 4993-5002.
9. Erdmann E, Charbonnel B, Wilcox RG etal. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PROactive study (PROactive 08). Diabetes Care. 2007; 30: 2773-2778.
10. Erdmann E, Dormandy JA, Charbonnel B etal. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) study. J Am Coll Cardiol. 2007; 49: 1772-1780.
11. Wilcox R, Kupfer S, Erdmann E, PROactive Study Investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008; 155: 712-717.
12. Mahaffey KW, Hafley G, Dickerson S etal. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013; 166: 240-249.e1.
13. Scirica BM, Bhatt DL, Braunwald E etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326.
14. White WB, Cannon CP, Heller SR etal. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-1335.
15. Scirica BM, Braunwald E, Raz I etal. Heart failure, saxagliptin and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130: 1579-1588.
16. Best JH, Hoogwerf BJ, Herman WH etal. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: A retrospective analysis of the LifeLink database. Diabetes Care. 2011; 34: 90-95.
17. Gejl M, Starup-Linde J, Scheel-Thomsen J, Gregersen S, Vestergaard P. Risk of cardiovascular disease: The effects of diabetes and anti-diabetic drugs. A nested case-control study. Int J Cardiol. 2015; 178: 292-296.
18. Marso SP, Poulter NR, Nissen SE etal. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013; 166: 823-830.
19. Nardev Khurmi (AstraZeneca). Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01144338 (accessed 3 March 2015).
20. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97: 4605-4612.
21. Dormandy JA, Charbonnel B, Eckland DJ etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005; 366: 1279-1289.
22. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA. 2007; 298: 1180-1188.
23. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: A population-based retrospective cohort study. JACC Heart Fail. 2014; 2: 573-582.
24. Zannad F, Cannon C, Cushman W etal. Alogliptin in patients with Type 2 Diabetes after acute coronary syndromes: Heart failure outcomes and cardiovascular safety in Heart failure patients. J Am Coll Cardiol. 2014; 63: 12_S. doi:10.1016/S0735-1097(14)60117-0.
25. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: Retrospective population based cohort study. BMJ. 2013; 346: f2267.
26. Navaneethan SD, Jolly SE, Schold JD etal. Development and validation of an electronic health record-based chronic kidney disease registry. Clin J Am Soc Nephrol. 2011; 6: 40-49.
27. Pantalone KM, Kattan MW, Yu C etal. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: A retrospective analysis. Acta Diabetol. 2009; 46: 145-154.